|
Powered by Cell Signaling Technology |
Moritz A (2003) CST Curation Set: 86; Year: 2003; Biosample/Treatment: cell line, K562/pervanadate; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 |
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here. |
Click on the protein name to open the protein page, and on the RSD number to open the site page.
|
Download |
Y223-p - Btk (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y225-p - Btk (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y296-p - DOK1 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y362-p - DOK1 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y377-p - DOK1 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y251-p - EIF2A (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y545-p - GIT1 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y611-p - HSP70 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y835-p - NICE-4 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y835-p - NICE-4 iso2 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y1774-p - NuMA-1 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y986-p - SHIP-2 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y20-p - TfR (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y280-p - TSAd (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y290-p - TSAd (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Y840-p - UBAP2 (human) ▲ | |||||||||
---|---|---|---|---|---|---|---|---|---|
|